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Introduction: Endometrial cancer patients with high grade tumours, deep myometrial inva-
sion or advanced stage disease have a poor prognosis. Randomised studies have demon-
strated the prevention of loco-regional relapses with radiotherapy (RT) with no effect on
overall survival (OS). The possible additive effect of chemotherapy (CT) remains unclear.
Two randomised clinical trials (NSGO-EC-9501/EORTC-55991 and MaNGO ILIADE-III) were
undertaken to clarify if sequential combination of chemotherapy and radiotherapy
improves progression-free survival (PFS) in high-risk endometrial cancer. The two studies
were pooled.
Methods: Patients (n = 540; 534 evaluable) with operated endometrial cancer International
Federation of Obstetrics and Gynaecology (FIGO) stage I–III with no residual tumour ander Ltd. All rights reserved.
fax: +46 46 188143.
se (T. Hogberg).
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Randomised clinical trialprognostic factors implying high-risk were randomly allocated to adjuvant radiotherapy
with or without sequential chemotherapy.
Results: In the NSGO/EORTC study, the combined modality treatment was associated with
36% reduction in the risk for relapse or death (hazard ratio (HR) 0.64, 95% confidence inter-
val (CI) 0.41–0.99; P = 0.04); two-sided tests were used. The result from the Gynaecologic
Oncology group at the Mario Negri Institute (MaNGO)-study pointed in the same direction
(HR 0.61), but was not significant. In the combined analysis, the estimate of risk for relapse
or death was similar but with narrower confidence limits (HR 0.63, CI 0.44–0.89; P = 0.009).
Neither study showed significant differences in the overall survival. In the combined anal-
ysis, overall survival approached statistical significance (HR 0.69, CI 0.46–1.03; P = 0.07) and
cancer-specific survival (CSS) was significant (HR 0.55, CI 0.35–0.88; P = 0.01).
Conclusion: Addition of adjuvant chemotherapy to radiation improves progression-free sur-
vival in operated endometrial cancer patients with no residual tumour and a high-risk pro-
file. A remaining question for future studies is if addition of radiotherapy to chemotherapy
improves the results.
 2010 Elsevier Ltd. All rights reserved.1. Introduction
Endometrial cancer is the most common gynaecologic cancer
in the Western world. It was estimated that worldwide around
200,000 women acquired and 50,000 died of endometrial can-
cer in 2002.1 The prognosis for early-stage endometrial cancer
is excellent, but subgroups with a high risk for micrometa-
static disease have been identified.2 Randomised studies dem-
onstrate high loco-regional control in early-stage endometrial
cancer with adjuvant pelvic external radiotherapy (RT).3–6
However, overall survival (OS) remains largely unaffected. It
is therefore likely that patients at risk for micrometastatic dis-
ease will benefit from systemic adjuvant therapy.
The Nordic Society of Gynaecological Oncology/European
Organisation for the Research and Treatment of Cancer
(NSOG/EORTC) trial was designed to investigate if the addition
of systemic chemotherapy (CT) to pelvic RT would improve
progression-free survival (PFS) and OS for patients with endo-
metrial cancer at high risk for micrometastatic disease. After
presentation of the preliminary results at the American Soci-
ety of Clinical Oncology (ASCO) 20077 it was decided to pub-
lish the study together with the results from a similar trial
(ILIADE-III) performed by the Gynaecological Oncology group
at the Mario Negri Institute (MaNGO). The results of the ILI-
ADE-III were not known.
When these studies were planned Thigpen and colleagues
had presented their randomised trial of doxorubicin + cis-
platin versus doxorubicin at ASCO 1993.8 This regimen was
chosen in both studies.
We report the results of the NSGO/EORTC and the MaNGO-
trials and an analysis of the pooled data.
2. Materials and methods
2.1. The NSGO-9501/EORTC-55991 trial
The inclusion criteria were histologically verified endometrial
cancer, surgery with total abdominal hysterectomy and bilat-
eral salpingo-oophorectomy (lymphadenectomy (LA) was op-
tional), no residual postoperative macroscopic tumour,International Federation of Obstetrics and Gynaecology (FIGO)
1988 surgical stage I, age 680 years, World Health Organisa-
tion performance status <3 and adequate bone marrow, liver
and kidney function. The risk assessment was based on FIGO
stage, grade and myometrial invasion. Most Swedish depart-
ments also used DNA ploidy. Patients were eligible if they
had a risk profile that qualified for adjuvant treatment. Pa-
tients with serous, clear cell or anaplastic carcinomas were
eligible regardless of other risk factors. Exclusion criteria
were: para-aortic lymph node involvement, squamous carci-
noma or small cell carcinoma with neuroendocrine differen-
tiation, pre-operative irradiation and previous or concurrent
malignant disease except for curatively treated carcinoma
in situ of the cervix or basal cell carcinoma of the skin.
Amendment 1 August 2002 (237 patients included) allowed
inclusion of patients with FIGO 1988 occult stage II, stage IIIA
(only positive peritoneal fluid cytology) and stage IIIC (only
positive pelvic lymph nodes without postoperative macro-
scopic residual tumour).
Randomisation was performed centrally by the study of-
fice at Linkoping University Hospital for NSGO patients and
at the EORTC Headquarters for EORTC patients. NSGO pa-
tients were randomised in blocks with stratification for centre
and histology. The EORTC used a minimisation procedure
with the same stratification factors.9
Pelvic RT was given according to departmental guidelines
(P44 Gy). RTwas given before CTin the sequential radiotherapy
and chemotherapy (RT–CT)-arm. Optional vaginal brachyther-
apy had to be decided before randomisation. Amendment 1
allowed the choice of sequence of RTand CT before randomisa-
tion. CT consisted of four courses of doxorubicin/epirubicin
50 mg/m2 + cisplatin 50 mg/m2 every 4 weeks. Amendment
2 on August 2004 (291 patients included) allowed alternative
CT regimens, including: paclitaxel 175 mg/m2 + epirubicin
60 mg/m2 or doxorubicin 40 mg/m2 + carboplatin AUC 5 or
paclitaxel 175 mg/m2 + carboplatin AUC 5–6 every 3 weeks.
Patients were followed at 3 and 6 months after treatment
and thereafter every 6 months for 5 years. A gynaecological
examination was performed at each visit. A chest X-ray was
to be taken annually.
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In 1996, the MaNGO group started the multicentre ILIADE-
study in endometrial cancer, which consisted of three proto-
cols. ILIADE-I investigated different techniques for hysterec-
tomy,10 ILIADE-II the question of LA11 and ILIADE-III
adjuvant therapy.
The inclusion criteria for ILIADE-III were histologically
confirmed endometrioid carcinoma, FIGO 1988 stage IIB,
IIIA–C disease (stage IIIA with positive cytology alone without
other risk factors was not included). Exclusion criteria: ser-
ous/clear cell carcinomas, performance status >2, previous
malignancy except for basal cell carcinoma of the skin, surgi-
cal procedures less than total abdominal hysterectomy and
bilateral salpingo-oophorectomy (LA was optional), previous
hormonal/chemo/radiotherapy for the present tumour, im-
paired cardiac function, evidence of any other serious disease
and inadequate bone marrow, liver or kidney function.
Patients were randomised in blocks that balanced the
treatment assignment within each site. Randomisation was
performed centrally by telephone at the Mario Negri Institute,
Milan.
CT had to start within 30 days after surgery and consisted
of doxorubicin 60 mg/m2 + cisplatin 50 mg/m2 every 3 weeks
for three cycles. The interval between CT and RT had to be
less than 4 weeks, while patients allocated to RT alone had
to start within 40 days after surgery. Pelvic RT was given with
1.8 Gy fractions; total dose 45 Gy. For patients with para-aortal
metastases, a para-aortal field was added up to L1/L2. Vaginal
brachytherapy was added for women with cervical stromal
involvement.
Patients were monitored every 3–4 months during the first
2 years, every 6 months for the next 3 years and then annu-
ally. The protocol recommended yearly computer tomography
or ultrasound of the pelvis and abdomen for the first 3 years.
The study protocols were reviewed and approved by the lo-
cal ethics committees. Informed consent was obtained from
all patients. Patients and staff were not blinded to the treat-
ment assignment.
2.3. Statistics
The primary end-point was PFS. All times were counted from
the time of randomisation. PFS was defined as the time to
progression of endometrial cancer or death from all causes.
Secondary end-points were OS; the time to death of all causes
and cancer-specific survival (CSS); the time to death related to
endometrial cancer.
Both studies aimed at detecting a 15% absolute improve-
ment in 5 year PFS from 60% to 75%. Assuming exponential
survival distributions this corresponds to a hazard ratio (HR)
of 0.56. Because of different assumptions about inclusion
and follow-up the number of patients in the NSGO/EORTC
and the MaNGO-trials was predetermined to 400 and 300,
respectively. The power calculation in the NSGO/EORTC-study
was based on OS.
The NSGO/EORTC and MaNGO databases were locked 19th
August 2009 and 6th March 2008, respectively. The intention-
to-treat principle was used in the analyses after exclusion of
five patients in the NSGO/EORTC-study (Fig. 1a) and one pa-tient with stage IV disease in the MaNGO-trial (Fig. 1b). Sur-
vival curves were constructed by the Kaplan–Meier
technique. Survival differences between groups were ex-
pressed as hazard ratios and were analysed with univariate
Cox proportional hazard models12 with stratification for
department. Departments which included less than four pa-
tients were aggregated within EORTC (n = 6) and MaNGO
(n = 9), respectively; all sites in the NSGO randomised four or
more patients. We also made a supportive Cox proportional
hazard model with age, stage, grade and cell type as covari-
ates to check if the treatment effect was affected. To analyse
potential heterogeneity of the treatment effect over sub-
groups, the interaction between treatment effect and group
variable was evaluated and illustrated with forest plots.13 Po-
tential heterogeneity among study groups and after amend-
ment 1 and 2 in the NSGO/EORTC-trial was analysed with
Cox-models and illustrated in a forest plot. Two-sided tests
were used for significance testing. We used Stata Version 10
(StataCorp, TX, USA).3. Results
Between May 1996 and January 2007, 383 patients were ran-
domised in the NSGO/EORTC study, 320 from 13 NSGO depart-
ments and 63 from 12 EORTC departments (Fig. 1a). In the
MaNGO-study, 157 patients from 20 departments were ran-
domised between October 1998 and July 2007 (Fig. 1b). The
treatment arms were well balanced regarding prognostic fac-
tors (Table 1).
Whether LA was performed was registered in EORTC pa-
tients and after amendment 2 in the NSGO. Twenty-eight
out of 61 patients in the RT-arm (46%) had a pelvic LA; eight
patients also underwent para-aortic LA. In the RT–CT-arm
35/72 (49%) underwent pelvic LA; six also underwent para-
aortic LA. In the MaNGO-trial 41/76 (54%) underwent system-
atic pelvic LA in the RT-arm; seven (9.2%) also had low para-
aortal and six (7.9%) high para-aortal LA. While 36/80 (45%)
in the RT–CT-arm underwent systematic pelvic LA; seven
(8.8%) and three (3.8%) had additional low or high para-aortic
LA (Table 1).
The compliance to RT was high in the NSGO/EORTC-study,
182/191 (95%) and 178/187 (95%) received P44 Gy in the RT-
arm and RT–CT-arm, respectively. Of the 187 patients as-
signed to CT, 136 (73%) received four treatment cycles as
planned. Eighteen (9.6%) received no CT and the CT data were
not available for three patients (1.6%) (Fig. 1a). Vaginal brach-
ytherapy was used in 75/191 (39%) of the cases in the RT-arm
and 82/187 (44%) in the RT–CT-arm (Table 1).
Most patients (138/166, 83%) received doxorubicin/epirubi-
cin + cisplatin, six patients (3.6%) epirubicin + carboplatin,
five (3%) paclitaxel + epirubicin + carboplatin and 17 (10%)
paclitaxel + carboplatin. Only 28 (17%) had CT before RT and
the sequence is unknown for seven (4%).
Eight patients (5.1%) in the MaNGO-trial did not undergo
RT. Patients assigned to RT or RT–CT received the same med-
ian pelvic RT dose (50 Gy). Seventy-one out of 80 patients
(89%) completed three courses of CT, three (3.8%) received less
than three courses, two (2.5%) did not start CT because of pa-
tients’ refusals and CT data were missing for four patients
5 excluded  
2 randomised to RT lost after 
randomisation before treatment 
could be given 
1 randomised to RT and 1 to 
RT-CT lost after reassessment 
of pathology after randomisation 
– no data 
1 randomised to RT-CT wrongly 
included (St IIIC) before amend-
ment II, no data 
Analysed  (n=191) 
191 allocated to RT 
182 received RT ≥44 Gy 
    4 received RT <44 Gy 
    2 did not receive RT 
    3 unknown if they received RT 
187 allocated to RT-CT 
178 received RT ≥44 Gy 
    3 received RT <44 Gy 
    3 did not receive RT 
    3 unknown if they received RT 
136 received 4 cycles of CT 
19 received 3 cycles of CT 
  3 received 2 cycles of CT 
  8 received 1 cycle of CT 
18 did not receive CT 
    3 unknown if they received CT 
    1 received neither RT nor CT 





Analysed  (n=76) 
76 Allocated to RT 
 
67 Received RT 
4 Did not receive RT 
5 Unknown if they received RT 
80 Allocated to RT-CT 
 
71 Completed 3 cycles of CT 
  3 Received <3 cycles of CT 
  2 Did not receive CT 
  4 Unknown if they received CT 
 
74 Received RT 
  4 Did not receive RT 
  2 Unknown if they received RT 
 
2 Received neither RT nor CT 





1 patient randomised to RT 
excluded because of violation of 
inclusion criteria; FIGO stage IVB 
a
b
Fig. 1 – (a) Consort flowchart NSGO/EORTC-study. (b) Consort flowchart ILIADE-study.
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brachytherapy. The corresponding figure in the RT–CT-arm
was 25/80 (31%) (Table 1).
In the NSGO/EORTC-trial, there was one treatment-related
death 3 months after randomisation in the RT-arm. No fur-
ther details were available. There were eight serious adverse
events (SAE) in the RT–CT-arm: two cases with diarrhoea,
one combined with neutropenia; three events with neutrope-
nia one with pneumonia requiring respirator treatment, andanother with associated nausea and vomiting; one patient
with allergic reaction to paclitaxel; one case with an episode
of atrial fibrillation; and one patient with bilateral pulmonary
emboli 24 days after cycle one. There was one SAE in the RT-
arm; an intestinal reaction with diarrhoea which led to cessa-
tion of RT after 36 Gy. All SAE’s resolved after appropriate
treatment.
In the MaNGO-trial no treatment-related death was regis-
tered. Analysis of toxicity was performed in 74 patients
Table 1 – Patient characteristics.
NSGO/EORTC-study MaNGO ILIADE-III study Total, n (%)
RT n (%) RT–CT n (%) RT n (%) RT–CT n (%)
Randomisation 191 187 76 80 534
Age
Median (range) 64 (44–79) 64 (38–83) 59 (42–78) 58 (39–77) 62(8–83)
FIGO stage
IA 27 (14) 17 (9.1) 0 0 44 (8.2)
IB 47 (25) 62 (33) 0 0 109 (20)
IC 98 (51) 92 (49) 0 0 190 (36)
II 2 (1.0) 3 (1.6) 0 0 5 (0.94)
IIA 10 (5.2) 7 (3.7) 0 1 (1.3) 18 (3.4)
IIB 0 2 (1.1) 22 (29) 29 (36) 53 (10)
IIIA 2 (1.0) 1 (0.53) 19 (25) 18 (23) 40 (7.5)
IIIB 0 0 0 1 (1.3) 1 (0.19)
IIIC 1 (0.52) 1 (0.53) 32 (42) 31 (39) 65 (12)
Unknown 4 (2.1) 2 (1.1) 3 (3.9) 0 9 (1.7)
Pelvic lymphadenectomy
No 33 (17) 37 (20) 32 (42) 44 (55) 146 (27)
Yes 28a (15) 35b (19) 41c (54) 36d (45) 140 (26)
Unknown 130 (68) 115 (61) 3 (3.9) 0 248 (46)
Vaginal brachytherapy
No 106 (56) 96 (51) 43 (57) 46 (58) 291 (54)
Yes 75 (39) 82 (44) 21 (28) 25 (31) 203 (38)
Unknown 10 (5.2) 9 (4.8) 12 (16) 9 (11) 40 (7.5)
Grade
Grade 1 19 (10) 15 (8.0) 3 (4.0) 7 (8.8) 44 (8.2)
Grade 2 36 (19) 31 (17) 36 (47) 46 (58) 149 (28)
Grade 3 92 (48) 108 (58) 34 (45) 27 (34) 261 (49)
Not assigned or unknowne 44 (23) 33 (18) 3 (3.9) 0 80 (15)
Cell type
Endometrioid 112 (59) 116 (62) 72 (95) 77 (96) 377 (71)
Adenosquamous 3 (1.6) 4 (2.1) 0 0 7 (1.3)
Serous 40 (21) 34 (18) 0 1 (1.3) 75 (14)
Clear cell 36 (19) 30 (16) 0 1 (1.3) 67 (12)
Anaplastic 0 2 (1.1) 1 (1.3) 1 (1.3) 4 (0.75)
Unknown 0 1 (0.53) 3 (3.9) 0 4 (0.75)
Ploidy
Non-diploid 59 (31) 63 (34) – – 122 (23)
Diploid 37 (19) 38 (20) – – 75 (14)
Polyploid 3 (1.6) 7 (3.7) – – 10 (1.9)
Unknown 92 (48) 79 (42) 76 (100) 80 (100) 327 (61)
Abbreviations: FIGO: International Federation of Gynaecology and Obstetrics, RT: radiotherapy and RT–CT: sequential radiotherapy and
chemotherapy.
a Eight of 28 patients also underwent para-aortal LA.
b Six of 35 patients also underwent para-aortal LA.
c Seven of 41 patients also underwent low para-aortal LA and six high para-aortal LA.
d Seven of 36 patients also underwent low para-aortal LA and three high para-aortal LA.
e Of the 80 with grade not assigned or unknown, 30 had serous, 36 clear cell carcinomas and one had anaplastic carcinoma.
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doxorubicin doses per cycle were 50 (25th–75th percen-
tiles = 49–50) and 60 (25th–75th percentiles = 56–60) mg/m2,
respectively. The maximum grades of toxicities observed dur-
ing treatment were: grade 3/4 leucopenia in 12 patients (16%);
grade 3/4 neutropenia in 22 (30%); grade 2 thrombocytopenia
in seven (9%); grade 2 anaemia in seven (9%); grade 3/4 nausea
and vomiting in four (5%); and grade 2/3 alopecia in 37 (50%).
Disease progression was registered in 46/191 (24%) and 28/
187 (15%) patients in the RT- and RT–CT-arm, respectively inthe NSGO/EORTC-study. The corresponding figures for the
MaNGO-trial were 24/76 (32%) and 15/80 (19%). Table 2 shows
the progression sites.
The difference in PFS between the treatment groups in the
NSGO/EORTC-trial was significant, favouring RT–CT with, HR
0.64 (95% CI 0.41–0.99) P = 0.04 (Table 3). In the MaNGO-trial
we found a non-significant difference of about the same mag-
nitude (HR 0.61) (Table 3). When pooling the data from both
studies there was a highly significant difference favouring
RT–CTwith HR 0.63 (95% CI 0.41–0.99) P = 0.009 (Fig. 2, Table 3).
Table 2 – Sites of progression.
RTn (%) RT–CTn (%)
Loco-regional 11 (16) 5 (12)
Distant 52 (74) 35 (81)
Unknown/multiple sites 7 (10) 3 (7.0)
Total 70 (100) 43 (100)
Abbreviations: RT: radiotherapy and RT–CT: sequential radiotherapy
and chemotherapy.
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showed significant differences in OS. The analysis of the
pooled data approached statistical significance with HR 0.69
(95% CI 0.46–1.03) P = 0.07 (Fig. 3, Table 3). The OS curves are
almost equal up to about 2 years and then they tend to split
up in favour of RT–CT.
The difference favouring RT–CT was significant for CSS in
the NSGO/EORTC-trial with HR 0.51 (95% CI 0.28–0.90)
P = 0.02, but not in the MaNGO-trial (HR 0.65). There was a sig-
nificant difference in the pooled data favouring RT–CT with
HR 0.55 (95% CI 0.35–0.88) P = 0.01 (Table 3).
A Cox proportional hazard model on 447 patients with no
missing values in any of the covariates (214 randomised to
RT and 233 to RT–CT) with age, stage, grade and cell type as
covariates, stratification for department and PFS as the end-
point demonstrated that the treatment effect was stable after
adjustment for prognostic factors. The HR was 0.65 (95% CITable 3 – Results of survival analyses in different groups.
End-point Events HR
RT % RT–CT % Total
NSGO-EC-9501/EORTC-55991 (RT n = 191, RT–CT n = 187)
PFS 50 26 35 19 85 0.64
OS 40 21 28 15 68 0.66
CSS 34 18 19 10 53 0.51
MaNGO ILIADE-III (RT n = 76, RT–CT n = 80)
PFS 26 34 18 23 44 0.61
OS 17 22 14 18 31 0.74
CSS 15 20 11 14 26 0.65
POOLED NSGO-EC-9501/EORTC-55991 + MaNGO ILIADE-III (RT n = 2
PFS 76 28 53 20 129 0.63
OS 57 21 42 16 99 0.69
CSS 49 18 30 11 79 0.55
NSGO-EC-9501/EORTC-55991 endometrioid carcinoma (RT n = 115, R
PFS 29 25 19 16 48 0.50
OS 25 22 15 13 40 0.55
CSS 22 19 11 9 33 0.42
NSGO-EC-9501/EORTC-55991 serous and clear cell carcinoma (RT n =
PFS 21 28 16 25 37 0.83
OS 15 20 13 20 28 0.94
CSS 12 16 8 13 20 0.71
POOLED NSGO-EC-9501/EORTC-55991 + MaNGO ILIADE-III endomet
PFS 54 29 35 18 89 0.53
OS 41 22 27 14 68 0.60
CSS 36 19 21 11 57 0.51
Abbreviations: CI: confidence interval, CSS: cancer-specific survival, HR:
radiotherapy and RT–CT: sequential radiotherapy and chemotherapy.0.43–0.99) compared to 0.63 (95% CI 0.42–0.93) without adjust-
ment for covariates. The analysis of heterogeneity of treat-
ment effect on PFS in patient subgroups was performed on
the same patients as the Cox model above, except that three
further patients with anaplastic/undifferentiated tumours
were excluded. LA could only be analysed in the subset where
this was registered (n = 286). There was no evidence of heter-
ogeneity of treatment effect with regard to age, grade, stage,
cell type or LA (Fig. 4). Fig. 5 shows another forest diagram
exploring if there was heterogeneity between study groups
and amendments in the NSGO/EORTC trial. As can be seen
the treatment effect is similar.
The apparent lack of effect in serous and clear cell carcino-
mas led to an unplanned data-driven subgroup analysis of
endometrioid carcinomas in the pooled population (n = 384).
For PFS, the HR was 0.53 (95% CI 0.34–0.83) P = 0.005 which
translates to 11% absolute difference in 5-year survival from
69% to 80% favouring RT–CT. Even OS was of borderline signif-
icance, HR 0.60; P = 0.05 (Table 3). For the 140 patients with
serous or clear cell carcinoma in the NSGO/EORTC-study,
the HR for PFS was 0.83 (95% CI 0.42–1.64) P = 0.59 (Table 3).4. Discussion
The NSGO/EORTC-trial showed that the sequential addition of
CT to RT was associated with a significant 36% reduction in
the risk of relapse or death and a significant 49% reduction95% CI P 5-Year probability of survival
RT RT–CT
0.41–0.99 0.04 0.72 0.79
0.40–1.08 0.10 0.76 0.83
0.28–0.90 0.02 0.79 0.88
0.33–1.12 0.10 0.61 0.74
0.36–1.52 0.41 0.73 0.78
0.30–1.44 0.29 0.76 0.82
67, RT–CT n = 267)
0.44–0.89 0.009 0.69 0.78
0.46–1.03 0.07 0.75 0.82
0.35–0.88 0.01 0.78 0.87
T–CT n = 120)
0.27–0.95 0.03 0.73 0.83
0.28–1.09 0.08 0.75 0.86
0.19–0.93 0.03 0.76 0.92
76, RT–CT n = 64)
0.42–1.64 0.59 0.71 0.72
0.42–2.08 0.88 0.78 0.77
0.26–1.90 0.49 0.82 0.85
rioid carcinoma (RT n = 187, RT–CT n = 197)
0.34–0.83 0.005 0.69 0.80
0.36–1.00 0.05 0.74 0.84
0.29–0.91 0.02 0.77 0.87
hazard ratio, OS: overall survival, PFS: progression-free survival, RT:
Fig. 2 – Progression-free survival in the pooled NSGO-EC-
9501/EORTC-5591 and MaNGO studies (CI: confidence
interval, HR: hazard ratio, RT: radiotherapy and RT–CT:
sequential radiotherapy and chemotherapy).
Fig. 3 – Overall survival in the pooled NSGO-EC-9501/EORTC-
5591 and MaNGO studies (CI: confidence interval, HR:
hazard ratio, RT: radiotherapy and RT–CT: sequential radio-
therapy and chemotherapy).
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the MaNGO-trial point in the same direction but are not sig-
nificant, likely because of the small study population. The
NSGO/EORTC- and MaNGO-trials addressed the same ques-
tion but in slightly different patient groups. The NSGO/
EORTC-trial initially included only patients with FIGO stage I
disease, but later also allowed inclusion of stage II and III.
However, relatively few patients with higher stages were in-
cluded. The MaNGO-trial included patients with more ad-
vanced stage disease (FIGO stage II–III). Serous/clear cell
carcinomas were included in the NSGO/EORTC-trial while
they were excluded in ILIADE. Otherwise, these two random-
ised studies were fairly similar and it seemed reasonable topool the data to increase the statistical power and get a more
representative stage distribution. With pooled data the esti-
mates were similar but with narrower confidence limits.
The 31% risk reduction of death from any cause in the pooled
data still only approached statistical significance. Endome-
trial cancer mainly affects elderly women and the risk of
death due to intercurrent disease is fairly high. There was a
significant 45% risk reduction when looking at cancer-specific
survival (CSS).
Endometrial cancer is a radiosensitive tumour. Adjuvant
external RT prevents the majority of pelvic disease progres-
sions, but many patients still die of distant metastatic dis-
ease.3–6,14 It has long been obvious that an effective
systemic adjuvant therapy should be added to or replace
adjuvant RT. The first randomised study (GOG-34) on adjuvant
CT in endometrial cancer was initiated by the US Gynecologic
Oncology Group (GOG) already in 1977.15 After adjuvant pelvic
external RT, patients were randomised to observation or to re-
ceive doxorubicin. The study was terminated prematurely be-
cause of slow recruitment and no significant difference in OS
or PFS could be found between the treatment arms.
GOG-122 included 396 evaluable patients with FIGO stage
III or IV endometrial carcinoma of any histology who after
surgery were randomised to CT (eight cycles of a doublet reg-
imen containing doxorubicin + cisplatin) or whole abdominal
RT.16 Both OS and PFS were significantly better for patients in
the CT arm. However, this was not a pure study of adjuvant
therapy since 16% of the patients had residual postoperative
tumours <2 cm.
In contrast, two other randomised studies, comparing RT
against CT, failed to show superiority of adjuvant CT versus
RT in terms of both disease-free survival and OS.17,18 RT was
compared with a three-drug regimen (cyclophospha-
mide + doxorubicin + cisplatin). Maggi and collegues17 sug-
gested that the two modalities may be complementary as
RT seemed to achieve better loco-regional control of the dis-
ease, while CT seemed to better control the distant spread.
The main difference between these trials and our study is
that we combined RT and CT in the experimental arm.
Limitations of our trials must be acknowledged. (1) The eli-
gibility criteria allowed inclusion of patients with several risk
levels of the disease. Although the 5-year survival rates in the
control arm were consistent with other similar trials4–6,17,18
the prognostic profile of many patients was rather favourable
and this might have reduced the statistical power. (2) We used
different CT regimens. However, all were well validated for the
salvage treatment of endometrial cancer. The majority (90%)
received a combination of anthracycline and platinum. The
aim of the studies was to find out if systemic therapy added
to RT could improve survival and not to evaluate the efficacy
of any specific regimen. We thought it appropriate to allow dif-
ferent regimens to increase inclusion rate. (3) Quality of life
data were only registered in some of the patients and have
not been analysed. (4) Lympadenectomy was optional and
was only registered and performed in a fraction of the patients.
A supportive Cox analysis of the pooled material from the
NSGO/EORTC and MaNGO showed that the treatment effect
on PFS remained unaffected with age, stage, grade and cell type
as covariates and we found no evidence that the PFS benefit for
RT–CT compared with RT differed within subgroups (stage
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Fig. 4 – Forest plots for interaction between prognostic factors and treatment. The analysis was performed on 444 patients
with no missing values for all covariates with progression-free survival (PFS) as the end-point. The analysis of
lymphadenectomy was performed on 286 patients with information about lymphadenectomy. The upper bar in each diagram
depicts the overall hazard ratio (HR) and the two middle bars show the HR by covariate group. The lowest bar shows the ratio
of hazard ratios (RHR), which is a measure of interaction; if it crosses the vertical line there is no significant interaction, which
is the case for all five covariates (RT: radiotherapy, RT–CT: sequential radiotherapy and chemotherapy).
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Fig. 5 – Forest plot with progression-free survival (PFS) as end-point illustrating possible heterogeneity depending on study
group (NSGO, EORTC or MaNGO) and original protocol, amendment 1 or 2 in the NSGO/EORTC-trial (CI: confidence interval,
HR: hazard ratio, RT: radiotherapy and RT–CT: sequential radiotherapy and chemotherapy).
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formed or not). It is interesting to note that for serous/clear cell
carcinomas, the treatment effect was negligible, although with
wide confidence intervals. The same tendency could be seen in
GOG-122,16 where the HR for death in the 83 women with ser-
ous carcinomas was slightly above 1.0 in contrast to the HR of
0.48 favouring CT for the endometrioid cell types. Chemother-
apy is often recommended for patients with serous/clear cell
carcinomas. However, neither the present study nor GOG-122
supports that recommendation. On the other hand, none of
the studies can rule out an effect.
We have shown that RT–CT seems superior to RT alone.
However, many important questions remain and need to be
clarified by future studies. The ongoing International Postop-
erative Radiotherapy in Endometrial Cancer study (PORTEC-3)
compares adjuvant pelvic RT with concomitant cisplatin fol-
lowed by four courses of paclitaxel + carboplatin (modified
from the The Radiation Therapy Oncology Group (RTOG)
trial19) with standard RT. Should the PORTEC-trial confirm
the superiority of the combined modality strategy it will still
be unsettled as to how much RT adds to CT. Before combining
two toxic therapies a study comparing RT–CT versus CT alone
should be done. The NSGO has made a proposal (After 4) in
the International Gynaecologic Cancer Intergroup (GCIG) set-
ting comparing four courses of paclitaxel + carboplatin fol-
lowed by RT versus six courses of paclitaxel + carboplatin.
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